For people living with chronic heart failure, everyday life can become increasingly difficult. The heart loses some of its ability to pump blood, leaving muscles and organs with less oxygen than they need.
This can lead to tiredness, swelling in the legs, breathlessness, and repeated hospital visits. Modern treatments have greatly improved survival, but they cannot cure the disease, and many patients continue to experience worsening symptoms.
One challenge is that medicines that make the heart squeeze harder can sometimes create new problems. Some raise the risk of abnormal heartbeats or affect blood pressure, making doctors cautious about their long-term use. Researchers have therefore been looking for safer ways to support the heart.
A research team led by Karolinska Institutet has taken an important early step by testing an experimental pill known as AC01. Their study was published in The Lancet. Instead of working like older heart-stimulating medicines, AC01 acts on the ghrelin receptor.
Although ghrelin is often called the hunger hormone because it helps control appetite, scientists now know it also has important effects in heart tissue. By using this pathway, researchers hope the drug can strengthen the heart without triggering many of the side effects associated with existing treatments.
The trial included 58 adults with stable chronic heart failure caused by reduced pumping function. Volunteers were randomly assigned to receive AC01 or a placebo for one or four weeks. The main goal was not to prove that the drug worked but to determine whether people could take it safely.
The findings were positive. Patients generally tolerated AC01 well, and the researchers did not identify any serious treatment-related side effects. They also found no signs that the medicine caused harmful changes in blood pressure or heart rhythm.
Although the study was small, tests suggested that the heart may have pumped more efficiently after treatment, with improvements in stroke volume and cardiac output.
These encouraging findings mean researchers can now move on to larger clinical trials. Future studies will need hundreds or even thousands of patients and longer follow-up periods. Those studies will determine whether AC01 can lower the risk of hospitalization, reduce symptoms, improve daily living, and extend survival.
Developing a new medicine takes many years. Most experimental drugs fail somewhere along the process because they are either unsafe or do not provide enough benefit.
Early studies like this one are therefore essential because they identify the treatments that deserve further testing. This project also involved researchers and clinicians from several European countries, highlighting the importance of international teamwork in medical research.
Review and analysis: The study offers promising but preliminary evidence. Its greatest strength is that it carefully evaluated safety using a randomized, placebo-controlled design. However, the trial was very small and lasted only a short time.
The improvements in heart pumping ability are interesting, but they are exploratory findings and cannot yet show that patients will feel better or live longer.
More extensive studies are needed before doctors can know whether AC01 represents a major advance in heart failure treatment. Until then, current guideline-recommended heart failure medicines remain the standard of care.
If you care about heart health, please read studies that yogurt may help lower the death risks in heart disease, and coconut sugar could help reduce artery stiffness.
For more information about health, please see recent studies that Vitamin D deficiency can increase heart disease risk, and results showing vitamin B6 linked to lower death risk in heart disease.
Source: Karolinska Institutet.
